See the DrugPatentWatch profile for keytruda

Keytruda, a medication developed by Merck & Co., was first approved by the U.S. Food and Drug Administration (FDA) for the treatment of metastatic melanoma in September 2014 [1]. Metastatic melanoma is a type of skin cancer that has spread to other parts of the body [2].

Keytruda, also known as pembrolizumab, is a type of immunotherapy that works by blocking the action of a protein called PD-1, which helps to keep the immune system from attacking cancer cells [3]. By blocking PD-1, Keytruda allows the immune system to better fight cancer cells [3].

It's important to note that Keytruda has since been approved for the treatment of several other types of cancer, including certain types of lung cancer, head and neck cancer, and Hodgkin lymphoma [1].

Sources:

* [1] <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-new-indications-keytruda-pembrolizumab-including-first-treatment-certain-types-lung-cancer>
* [2] <https://www.mayoclinic.org/diseases-conditions/melanoma/symptoms-causes/syc-20374883>
* [3] <https://www.drugpatentwatch.com/drugs/keytruda>